As a result, combinatorial approaches that integrate telomerase inhibition with other targeted therapies, such as Polo-like kinase 1 (PLK1) inhibitors, may be necessary to achieve sustained tumor control in HCC. The gene discussed is PLK1; the disease is neoplasm.